Astrana Health, Inc.
ASTH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -3.42 | 0.91 | -0.28 | 0.38 |
| FCF Yield | 0.53% | 7.06% | 0.90% | -0.89% |
| EV / EBITDA | -106.69 | 42.80 | 71.37 | 118.50 |
| Quality | ||||
| ROIC | 0.22% | 1.23% | 1.35% | 0.29% |
| Gross Margin | 8.53% | 11.91% | 11.50% | 9.47% |
| Cash Conversion Ratio | 26.69 | 9.65 | 2.67 | 1.41 |
| Growth | ||||
| Revenue 3-Year CAGR | 29.69% | 23.11% | 22.71% | 21.15% |
| Free Cash Flow Growth | -91.43% | 537.38% | 200.58% | -142.54% |
| Safety | ||||
| Net Debt / EBITDA | -33.02 | 3.47 | 8.12 | 12.82 |
| Interest Coverage | 1.08 | 2.76 | 2.82 | 0.09 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 15.79 | 47.97 | 45.23 | 41.68 |